Drug intelligence / Profile preview

Nosis-Kidney-001

Development stage: Preclinical
Lead developer: Nosis Biosciences
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

Nosis-Kidney-001 is an unnamed RNA-based therapeutic candidate being developed by Nosis Biosciences for the treatment of various renal diseases. The program utilizes Nosis Bio's proprietary tissue-targeted delivery platform, which is designed to overcome the historical challenges of delivering RNA medicines to extra-hepatic tissues. By leveraging a platform that identifies and targets novel receptors on specific cell types, Nosis aims to deliver RNA payloads directly to the kidney to modulate disease-relevant genetic pathways. As of 2025, the program is in the functional in vivo delivery validation stage of preclinical development.

Targets

LRP2 (Low-density lipoprotein receptor-related protein 2)

Beyond the preview

Go deeper on Nosis-Kidney-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nosis-Kidney-001.

Explore the full profile